Finally, we establish that combined administration of Akt (MK‐2206) and SGK (14h) inhibitors to mice bearing xenograft BT‐474 breast cancer tumours induces a striking tumour regression compared to when the inhibitors were administered individually. Here, AKT1 is linked to breast cancer.